Intrahepatic Arterial Delivery of Sorafenib Eluting Beads: A Pharmacokinetics Study

Authors

  • Eerdunbagena Ning Haikou People's Hospital of Hainan Province
  • Zhijun Wang Interventional Radiography of China PLA General Hospital

DOI:

https://doi.org/10.30564/jams.v3i2.1539

Abstract

 

Objective: To determine the slow-release effect of Sorafenib carried beads and its impact on the normal liver of dogs. Materials and Methods: (1) To obtain the maximal drug-carrying of beads, different sizes of beads (300-500 μm and 500-700 μm) were tried. Five bottles of different sizes of beads were added into 75% solution of Sorafenid-alcohol with different concentrations: Bottle a,50mg/20ml; Bottle b, 100mg/20ml; Bottle c, 100 mg/40ml; Bottle d, 200mg/40m; Bottle e, 250mg/50ml. (2) In vivo study: 12 dogs were randomly divided into four groups [group A, Sorafenib carried bead (500-700μm); group B, only bead (300-500μm) ; group C, Lipiodol-sorafenib and four dogs in each group. Each group was treated with TAE with emulsion mentioned above. Sorafenib concentration in plasma and liver tissue was determined with HPLC respectively. Result: (1) In vitro research: Sorafenib can be dissolved into 75% alcohol and the best concentration for drug-carrying was 100mg/20ml. (2) In vivo study: ① Compared with group D, the Cmax and AUC in plasma in group A and B has a significant statistics difference(p<0.05). ② Sorafenib concentration in liver tissue could be determined in group A in the 3rd day and even after one week while it could not be determined in group D. Conclusion: Sorafenib can be carried in DC-Bead in a certain condition. Compared with emulsion with Sorafenib and lipiodol, DC-bead has a definite slow-release function and it is superior to lipiodol.

Keywords:

Sorafenib; Transcatheter arterial embolization; Drug bearing microsphere; Experimental study

References

[1] Song MJ, Park CH, Kim JD,etal.Drug-eluting bead carried with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma:a case-control study of Asian patients[J].Eur J Gastroenterol Hepatol, 2011; 23(6):521-7.

[2] Seki N,Michel W,Jean MM,etal.Drug-eluting beads for liver embolization:concentration of doxorubicin in tissue and in beads in a pig model[J]. J Vasc Interv Radiol 2010; 21:259–267.

[3] Andrew L, Lewis M,Victoria G,etal.Doxorubicin eluting beads – 1: Effects of drug carrying on bead characteristics and drug distribution[J]..J Mater Sci: Mater Med, 2007, 18:1691–1699.

[4] M. Victoria G, Tang YQ, Gary J, etal.Doxorubicin eluting beads—2: methods for evaluating drug elution and in-vitro: in-vivo correlation[J]..J Mater Sci: Mater Med, 2008, 19:767–775.

[5] Zhao Susu, Zhang Dongsheng and Lu Qin Research progress in the preparation and application of intravascular drug-eluting stents. Journal of Southeast University (Medical Edition), 2007,26 (5): 378-381.（in Chinese）

[6] Guo Yanling, Feng Yumei. Progress in polymer research as anticancer drug carrier, Journal of Tianjin University of Science and Technology, 2004,19 (3): 11-14.（in Chinese）

[7] Xu Kaiyuan, Zou Yinghua, Qi Xianrong, etc. Effect of adriamycin alginate beads embolization on angiogenesis of VX2 transplanted tumor in rabbit liver. Chinese Medical Imaging Technology. 2010,26 (2): 217-220. （in Chinese）

[8] Lu Anlin, Xing Yujie, Wang Li, et al. The ability of rapamycin polylactide nanocomposites to affect the proliferation of vascular smooth muscle cells. China Tissue Engineering Research and Clinical Rehabilitation, 2010,14 (42): 7815-7818（in Chinese）

[9] Yuan Huiyan, Zhang Yuan, Fan Tianyuan, Preparation and properties of ion exchange embolic beads and Pingyangmycincarried DC-bead, Journal of Peking University (Medical Edition), 2009, 41 (2): 217-220（in Chinese）

[10] Kelvin H, Afsheen K, Eleni Li, et al.New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer.Clin Cancer Res 2006; 12:2563-2567.

[11] Hori S, Kobayashi K,Transcatheter Arterial Chemoembolization with Epirubicin-Carried Superabsorbent Polymer Beads for 135 Hepatocellular Carcinoma Patients: Single-Center Experience[J].Cardiovasc Intervent Radiol,2010 Sep 7. [Epub ahead of print].

[12] Mahmood U.Can a clinically used chemoembolization vehicle improve transgene delivery [J]? Radiology, 2006, 240:619-620.

[13] Richard E. J. Forster,Sharon A.Small,Yiqing Tang.Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer [J]. J Mater Sci: Mater Med, 2010, 21:2683–2690

[14] Eyol A，Rachel R，Andrew L，etal.Chemoembolisation of rat colorectal liver metastases with drug eluting beads carried with irinotecan or doxorubicinClin Exp Metastasis (2008) 25:273–282. Clin Exp Metastasis,2008; 25:273–282.

[15] Rachel R. , Yiqing T M. Victoria G,etal.Irinotecan drug eluting beads for use in chemoembolization:In vitro and in vivo evaluation of drug release propertieseuropean[J]. Journal of pharmaceutical sciences，2007，3 0: 7–14.

[16] Renumathy D, DAVID A. K, CHARLES A. S，etal., Comparison of Conventional Transarterial Chemoembolization (TACE) and Chemoembolization With Doxorubicin Drug Eluting Beads (DEB) for Unresectable Hepatocelluar Carcinoma (HCC) [J]. Journal of Surgical Oncology 2010; 101:476–480

[17] Kalayci,Marı′a V, Marı′a I ,Marta B.Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics.Journal of Hepatology,2007, e,46:474–481.

[18] Gadaleta CD, Ranieri G.Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions forcombination with angiogenesis inhibitors[J].Crit Rev Oncol Hematol. 2010 Nov 8. [Epub ahead of print].

[19] Adriana S, Chiara C, Romilda C,etal.Transcatheter arterial chemoembolization (TACE)in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103:914–921?

[20] Fiorentini G.A new tool to enhance the efficacy of chemoembolization to treat primary and metastatic hepatic tumors[J]. Expert Opin Drug Deliv.2011;8(4):409-13.

[21] Josep L, Sergio R, Vincenzo M,et al.Sorafenib in advanced hepatocellular carcinoma [J].N Engl J Med,2008,359(24):378-390.

[22] Mahmood U.Can a clinically used chemoembolization vehicle improve transgene delivery? [J] Radiology, 2006, 240:619-620.

[23] Liu L, Cao Y, Chen C, et al.Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66(24):11851-11858.

[24] Joachim K, Alfred S, Isabella K, etal.Drug-Carried Beads for the Treatment of Liver Cancer: Review of Current Results [J]..Cardiovasc Intervent Radiol (2008) 31:468–476.

[25] [25]Katerina M, Mary P, Alexis K,etal.Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with beadBlock for hepatocellular carcinoma[J].Cardiovasc Intervent Radiol ,2010,33:541–551

[26] Miyayama S, Yamashiro M, Okuda M, et al .Main Bile Duct Stricture Occurring After Transcatheter Arterial Chemoembolization for Hepatocellular.Carcinoma.Cardiovasc Intervent Radiol. 2010 Jan 8. [Epub ahead of print]

[27] Wang MQ, Shao RH, Ye HY, et al. Investigation of bile duct injury after transca theter arter ial chemoembolization. Zhonghua Zhong Liu Za Zhi.2005, 27:609-612.

[28] Barone M, Ettorre GC, Ladisa R , et al . Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. Hepatogastroenterology, 2003, 50:1832187.

Downloads

Issue

Vol. 3 , Iss. 2 (April 2020)

Article Type

Research Article

License

Copyright and Licensing

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

Journal of Advances in Medicine Science publishes accepted manuscripts under Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Authors who submit their papers for publication by Journal of Advances in Medicine Science agree to have the CC BY-NC 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for non-commercial use. As long as you follow the license terms and original source is properly cited, anyone may copy, redistribute the material in any medium or format, remix, transform, and build upon the material.

License Policy for Reuse of Third-Party Materials

If a manuscript submitted to the journal contains the materials which are held in copyright by a third-party, authors are responsible for obtaining permissions from the copyright holder to reuse or republish any previously published figures, illustrations, charts, tables, photographs, and text excerpts, etc. When submitting a manuscript, official written proof of permission must be provided and clearly stated in the cover letter.
The editorial office of the journal has the right to reject/retract articles that reuse third-party materials without permission.

Journal Policies on Data Sharing

We encourage authors to share articles published in our journal to other data platforms, but only if it is noted that it has been published in this journal.